Oppilotech and Evariste Technologies Partnered to Develop First-in-Class Antibacterial Programme

Oppilotech Ltd., a biotechnology company specializing in the systems biology and the machine learning platforms for the purpose of building the unique predictive computational models of cells has announced a partnership of co-development drug discovery with Evariste Technologies based in United Kingdom, that is going to be using the artificial intelligence and machine learning technologies for the purpose of establishing a first-in-class antibacterial programme in the United Kingdom.

The Oppilotech Ltd., has been utilising the systems company’s biology systems and machine learning platform for the purpose of building some of most detailed and computational models of bacteria that had been ever assembled.

All these high resolution models have been providing the deep insights into the biology of bacteria and also identifying the reliable targets for the intervention of the drugs, and this partnership has also been aiming for pursuing a drug target that is discovered by using the models of Oppilotech Ltd.

Ajay Mistry, founder and CEO of Oppilotech Ltd. Said that, there is a clear need for the novel antibacterial agents specifically against the hard for treatment Gram-negative group of the infections, and working with the Evariste Technologies will be allowing them to combine the cutting-edge technologies for the purpose of addressing the particular medical challenge and at Oppilotech Ltd., they are very focused at navigating the biology for the purpose of discovering the drugs.

Dr. Oliver Watson, founder of Evariste Technologies said, they are very happy for partnering with the Oppilotech Ltd., on the antimicrobial resistance that has been one of the greatest public health challenges of this century and using the machine learning and artificial intelligence technologies are going to be very much essential in tackling the fundamental threat to the society.